Recent studies have demonstrated that High-Intensity Focused Ultrasound (HIFU) is a promising treatment for localized prostate cancer, showing non-inferior outcomes compared to traditional radical prostatectomy. Specifically, a prospective trial presented at the American Urological Association (AUA) 2024 Annual Meeting reported a 30-month salvage treatment-free survival (STFS) rate of 90.1% for patients undergoing HIFU, compared to 87.6% for those who had radical prostatectomy. This highlights HIFU’s effectiveness in managing prostate cancer while minimizing the need for further interventions.
HIFU works by utilizing high-intensity ultrasound waves to precisely target and destroy cancerous tissue in the prostate. The procedure is minimally invasive, allowing for focused treatment without the need for extensive surgical intervention. During the process, ultrasound waves generate heat that can raise the temperature of targeted cancer cells to levels that lead to their destruction while sparing surrounding healthy tissue.
The success rates of HIFU treatments have been encouraging. In various studies, the failure-free survival rates were reported at 67.3% at two years and 53.8% at five years post-treatment. Additionally, a separate study showed that after 36 months, the cancer-specific survival rate was an impressive 100%, with 83% of patients remaining free from radical treatment. These results suggest that HIFU not only effectively controls cancer but also preserves quality of life by reducing complications such as erectile dysfunction and urinary incontinence.
Recently, EDAP TMS SA partnered with Avenda Health to launch robotic-assisted HIFU procedures, marking a significant advancement in this field. This collaboration aims to enhance the precision and effectiveness of HIFU treatments through the integration of robotic technology and artificial intelligence (AI). The use of AI will help in creating personalized treatment plans by analyzing patient-specific data and improving targeting accuracy during procedures.
Recently, EDAP TMS SA partnered with Avenda Health to launch robotic-assisted HIFU procedures, marking a significant advancement in this field. This collaboration aims to enhance the precision and effectiveness of HIFU treatments through the integration of robotic technology and artificial intelligence (AI). The use of AI will help in creating personalized treatment plans by analyzing patient-specific data and improving targeting accuracy during procedures.
HIFU has received approval from the U.S. Food and Drug Administration (FDA) for specific applications in treating localized prostate cancer, with significant advancements made in recent years. The FDA’s endorsement allows for broader use of this innovative technology, providing patients with a viable alternative to more invasive surgical options.
In summary, HIFU represents a significant advancement in the treatment of localized prostate cancer, offering comparable outcomes to traditional methods while enhancing patient comfort and quality of life. With the recent partnership between EDAP and Avenda Health, along with UCLA’s pioneering role in HIFU research, the future of HIFU treatments looks even more promising as robotic assistance and AI integration could further improve patient outcomes and procedural efficiency.
These sources illustrate the collaborative efforts among various institutions and companies to enhance the application of HIFU in treating prostate cancer, emphasizing its growing acceptance and integration into clinical practice.
Leading in Face Lift, Anti-Aging & Liposuction, we excel in face contouring, lifting, and body reshaping through liposuction. Our primary goal is to ensure optimal outcomes for our patients.
Branch Big C. : Big C Supercenter 1st floor (opposit to KFC), Amphoe Muang Phuket, Phuket, Thailand 83000
BISP Branch : 189 Supicha Sino, Ko Kaeo, Muang, Phuket 83000
© Design by Digital Doctor 2025
